Dolutegravir 50mg / Abacavir 600mg / Lamivudine 300mg tablets
NHS hospitals in England used £45,361,748 of indicative cost of Dolutegravir 50mg / Abacavir 600mg / Lamivudine 300mg tablets in the 12 months to April 2026, about 0.2% of all hospital medicines spend. That is down 9.4% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Dolutegravir 50mg / Abacavir 600mg / Lamivudine 300mg tablets: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Dolutegravir 50mg / Abacavir 600mg / Lamivudine 300mg tablets most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Nottingham University Hospitals Trust | £2,844,695 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £2,821,708 |
| Manchester University Nhs Ft | £2,694,588 |
| South Warwickshire Nhs Foundation Trust | £2,558,103 |
| Guy's & St Thomas' Nhs Foundation Trust | £2,310,673 |
| Colchester Hospital University Nhs Ft | £2,067,234 |
| Leeds Teaching Hpls Nhs Trust | £1,970,657 |
| Derby Teaching Hospitals Nhs Found Trust | £1,787,080 |
| London North West Healthcare Nhs Trust | £1,687,310 |
| Univ Hpl B/Ham Nhs Foundation Trust | £1,492,745 |
The primary-care picture
Dolutegravir is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Dolutegravir medicine page.